Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CNTN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
CNTN holds $37.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $4.9M/quarter from operations, an estimated runway of 22.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 53 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CNTN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Murtaza S. Akbar | 5%+ holder (13G) | 6,203,724 | 7.60% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,819,281 | 5.90% | 2026-09-30 |
| Broadridge Financial Solutions, Inc. | 5%+ holder (13G) | 4,187,548 | 5.13% | 2026-01-30 |
| LCV Fund VIII, L.P. | 5%+ holder (13G) | 4,044,927 | 4.95% | 2026-01-30 |
| Vincent S LoPriore Executive Chairman, Director, 10% owner · +190,000 options |
Insider | 732,424 | 0.90% | 2025-04-09 |
| Gravitas Capital LP 10% owner · +190,000 options Includes shares also reported by Vincent S LoPriore, counted once |
Insider | 732,424 | 0.90% | 2025-06-20 |
| Gary S. Stetz Director · +82,500 options |
Insider | 134,175 | 0.16% | 2026-05-22 |
| Sireesh Appajosyula CEO, Director · +547,886 options |
Insider | 64,868 | 0.08% | 2025-06-20 |
| Randy Milby CEO, Director · +138,665 options |
Insider | 17,534 | 0.02% | 2024-12-19 |
| Kelly Anderson Director · +52,353 options |
Insider | 6,300 | 0.01% | 2025-06-23 |
| Sanam Parikh COO, Director · +105,000 options |
Insider | 1,770 | 0.00% | 2025-06-20 |
Share count 81,638,745 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CNTN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →